Once a niche topic in endocrinology, this naturally occurring gut hormone has been thrust into the global spotlight, heralded as a revolutionary tool in the management of type 2 diabetes and, most notably, weight loss
With BioNeMo running on Roches Blackwell GPUs, scientists can train or fine-tune large language models (LLMs) or diffusion models on protein/genomics/compound data
GLP-1 receptor agonists reduce alcohol intake: Evidence from preclinical and clinical studies
Recommended Reading and Primary Sources FDA approval coverage (plain-language reporting) AP News: FDA approves pill version of Wegovy, with trial headline results and dosing constraints summarized
Because GLP-2 acts through subepithelial myofibroblasts, which are the same cell population implicated in intestinal fibrogenesis, the risk-benefit profile of GLP-2 agonism may differ substantially between mucosal UC, inflammatory ileal CD, and stricturing or penetrating CD phenotypes, and this phenotypic stratification should be a required feature of future trial design
In the preclinical literature it is described above all as a cytoprotective and pro-angiogenic compound, acting locally within damaged tissue